Anavex Life Sciences Corp (AVXL)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Anavex Life Sciences Corp (AVXL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013546
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Anavex Life Sciences Corp (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, other central nervous system (CNS) diseases, pain and various types of cancer. The company’s target indications include Alzheimer’s disease, Parkinson’s disease, Rett syndrome, epilepsy, neuropathic pain, depression, prostate cancer, pancreatic cancer and malignant melanoma. Its pipeline comprises one drug candidate and several compounds in diverse stages of pre-clinical study. Anavex’s lead compound ANAVEX 2-73 is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and potentially other CNS diseases, including rare diseases. Anavex is headquartered in New York, the US.

Anavex Life Sciences Corp (AVXL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Anavex Life Sciences Corp, Medical Devices Deals, 2011 to YTD 2017 10
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Anavex Life Sciences Enters into Partnership with Ariana Pharmaceuticals 12
Anavex Enters Into Agreement With Roskamp Institute To Develop ANAVEX PLUS 13
Licensing Agreements 14
Anavex Enters Into Licensing Agreement With Life Science Research Israel 14
Equity Offering 15
Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD29 Million 15
Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD100 Million 16
Anavex Life Sciences to Raise USD0.5 Million in Private Placement of Shares and Warrants 17
Anavex Life Sciences Announces Private Placement Of Units For US$2.6 Million 18
Anavex Life Sciences Completes First Tranche Of Private Placement Of Shares For US$0.1 Million 19
Anavex Life Sciences Raises US$1.6 Million Upon Exercise Of Warrants 20
Debt Offering 21
Anavex Life Sciences Completes Private Placement Of Debenture For US$10 Million 21
Anavex Life Sciences Corp – Key Competitors 22
Anavex Life Sciences Corp – Key Employees 23
Anavex Life Sciences Corp – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 07, 2017: Anavex Reports Fiscal Third Quarter 2017 Financial Results 25
May 10, 2017: Anavex Reports Fiscal Second Quarter 2017 Financial Results 27
Feb 07, 2017: Anavex Reports Fiscal First Quarter 2017 Financial Results 28
Aug 11, 2016: Anavex Reports Fiscal Third Quarter 2016 Financial Results 29
May 11, 2016: Anavex Reports Fiscal Second Quarter 2016 Financial Results 30
Feb 08, 2016: Anavex Reports Fiscal First Quarter 2016 Financial Results 31
Corporate Communications 32
Jul 20, 2017: Anavex Life Sciences appoints scientific advisory board member 32
May 01, 2017: Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President of Regulatory Affairs 33
Feb 13, 2017: Anavex Life Sciences Strengthens Board of Directors 34
Legal and Regulatory 35
Mar 30, 2017: Anavex Life Sciences Reports Dismissal of Appeal in the Cortina Lawsuit 35
Jan 03, 2017: Anavex Life Sciences Obtains Permanent Dismissal of All Claims in Securities Lawsuit 36
Product News 37
Nov 21, 2017: Anavex Life Sciences Reports Newly Published Data on Alzheimer’s Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor 37
Clinical Trials 38
Mar 10, 2016: Anavex Announces Two-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response Analysis at AAT Conference 38
Feb 25, 2016: Anavex Presents Preclinical Results of ANAVEX 2-73 in Rett Syndrome 39
Feb 17, 2016: ANAVEX 2-73 Preclinical Data in New Indication to be Presented at ACTRIMS 2016 40
Jan 11, 2016: Anavex Announces Positive Dose-Response Data for ANAVEX 2-73 in Alzheimer Disease Patients 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Anavex Life Sciences Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Anavex Life Sciences Corp, Medical Devices Deals, 2011 to YTD 2017 10
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Anavex Life Sciences Enters into Partnership with Ariana Pharmaceuticals 12
Anavex Enters Into Agreement With Roskamp Institute To Develop ANAVEX PLUS 13
Anavex Enters Into Licensing Agreement With Life Science Research Israel 14
Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD29 Million 15
Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD100 Million 16
Anavex Life Sciences to Raise USD0.5 Million in Private Placement of Shares and Warrants 17
Anavex Life Sciences Announces Private Placement Of Units For US$2.6 Million 18
Anavex Life Sciences Completes First Tranche Of Private Placement Of Shares For US$0.1 Million 19
Anavex Life Sciences Raises US$1.6 Million Upon Exercise Of Warrants 20
Anavex Life Sciences Completes Private Placement Of Debenture For US$10 Million 21
Anavex Life Sciences Corp, Key Competitors 22
Anavex Life Sciences Corp, Key Employees 23

★海外企業調査レポート[Anavex Life Sciences Corp (AVXL)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Suzlon Energy Ltd (SUZLON):企業の財務・戦略的SWOT分析
    Suzlon Energy Ltd (SUZLON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Ashok Leyland Limited:企業の戦略・SWOT・財務分析
    Ashok Leyland Limited - Strategy, SWOT and Corporate Finance Report Summary Ashok Leyland Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Honeywell Advanced Fibers and Composites:企業の戦略・SWOT・財務情報
    Honeywell Advanced Fibers and Composites - Strategy, SWOT and Corporate Finance Report Summary Honeywell Advanced Fibers and Composites - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • National Gypsum Co:企業の戦略・SWOT・財務分析
    National Gypsum Co - Strategy, SWOT and Corporate Finance Report Summary National Gypsum Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Epsilon Energy Ltd (EPS):企業の財務・戦略的SWOT分析
    Summary Epsilon Energy Ltd (Epsilon) is an oil and gas company that provides exploration, exploitation and development of oil and gas reserves. The company provides projects such as Marcellus shale in northeast Pennsylvania, Bakken Shale and Midale Dolomite in Saskatchewan, among others. It operates …
  • bebe stores, inc.:企業の戦略・SWOT・財務分析
    bebe stores, inc. - Strategy, SWOT and Corporate Finance Report Summary bebe stores, inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • AB SKF (SKF B)-エネルギー分野:企業M&A・提携分析
    Summary AB SKF (SKF) is a manufacturer and supplier of bearing and seal products that include ball bearings, roller bearings, bearing accessories, truck runner bearings, super-precision bearings, plain bearings, bearing units, bearing housings, and automotive and industrial seal. SKF also offers lub …
  • Genzyme Corp:医療機器:M&Aディール及び事業提携情報
    Summary Genzyme Corp (Genzyme), a subsidiary of Sanofi, is a biotechnology company that develops specialty care treatments targeting rare diseases, oncology, immunology and multiple sclerosis. It offers products for the treatment of indications including various forms of cancer, mucopolysaccharidosi …
  • Brambles Limited (BXB):企業の財務・戦略的SWOT分析
    Brambles Limited (BXB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Global Telecom Holding SAE:企業の戦略的SWOT分析
    Global Telecom Holding SAE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • CARBO Ceramics Inc (CRR):企業の財務・戦略的SWOT分析
    CARBO Ceramics Inc (CRR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Affinity Water Ltd:企業の戦略的SWOT分析
    Affinity Water Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Exosomics Siena SpA:企業の製品パイプライン分析2018
    Summary Exosomics Siena SpA (Exosomics Siena) is a biotechnology company that offers research and development services. The company provides services such as contract research, collaborative project management, lead development and technological services. It offers technological services such as sam …
  • Greatcell Solar Ltd (GSL):企業の財務・戦略的SWOT分析
    Greatcell Solar Ltd (GSL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Lotte Chemical Corp (011170):企業の財務・戦略的SWOT分析
    Lotte Chemical Corp (011170) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • RegeneRx Biopharmaceuticals Inc (RGRX):企業の財務・戦略的SWOT分析
    Summary RegeneRx Biopharmaceuticals Inc (RegeneRx) is a clinical-stage biopharmaceutical company that designs, researches and develops novel peptides targeted at diseases with unmet medical needs. The company offers clinical trials, science and discovery and business development services. Its busine …
  • Casio Computer Co Ltd (6952):企業の財務・戦略的SWOT分析
    Casio Computer Co Ltd (6952) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Atomenergoprom:企業の戦略的SWOT分析
    Atomenergoprom - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Staffline Group plc:企業のM&A・事業提携・投資動向
    Staffline Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Staffline Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Zebra Technologies Corp (ZBRA):企業の財務・戦略的SWOT分析
    Zebra Technologies Corp (ZBRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆